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Abstract
Background: Bloodstream infection is a common cause of hospitalization, morbidity and death in children. The impact
of antimicrobial resistance and HIV infection on outcome is not firmly established.
Methods: We assessed the incidence of bloodstream infection and risk factors for fatal outcome in a prospective cohort
study of 1828 consecutive admissions of children aged zero to seven years with signs of systemic infection. Blood was
obtained for culture, malaria microscopy, HIV antibody test and, when necessary, HIV PCR. We recorded data on clinical
features, underlying diseases, antimicrobial drug use and patients' outcome.
Results: The incidence of laboratory-confirmed bloodstream infection was 13.9% (255/1828) of admissions, despite two
thirds of the study population having received antimicrobial therapy prior to blood culture. The most frequent isolates
were klebsiella, salmonellae, Escherichia coli, enterococci and Staphylococcus aureus. Furthermore, 21.6% had malaria and
16.8% HIV infection. One third (34.9%) of the children with laboratory-confirmed bloodstream infection died. The
mortality rate from Gram-negative bloodstream infection (43.5%) was more than double that of malaria (20.2%) and
Gram-positive bloodstream infection (16.7%). Significant risk factors for death by logistic regression modeling were
inappropriate treatment due to antimicrobial resistance, HIV infection, other underlying infectious diseases, malnutrition
and bloodstream infection caused by Enterobacteriaceae, other Gram-negatives and candida.
Conclusion: Bloodstream infection was less common than malaria, but caused more deaths. The frequent use of
antimicrobials prior to blood culture may have hampered the detection of organisms susceptible to commonly used
antimicrobials, including pneumococci, and thus the study probably underestimates the incidence of bloodstream
infection. The finding that antimicrobial resistance, HIV-infection and malnutrition predict fatal outcome calls for renewed
efforts to curb the further emergence of resistance, improve HIV care and nutrition for children.
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One in every six African children dies before the age of five
years [1]. The World Health Organization (WHO) rank
the major causes of mortality in African children younger
than five years as neonatal causes (26%, among which the
entity "sepsis or pneumonia" contributes a quarter),
pneumonia (21%), malaria (18%) diarrhea (16%) and
HIV-infection (6%) [2]. Bloodstream infection is a fre-
quent cause of morbidity and associated with mortality in
excess of 25% [3]. Since bloodstream infection may occur
as part of localized infections with defined foci such as
pneumonia and diarrhea, its importance is not reflected
in the above estimates of death causes. Bloodstream infec-
tion and malaria are practically indistinguishable by clin-
ical examination [4], and available WHO guidelines for
managing childhood illnesses fail to identify up to half of
the cases of bloodstream infections [5]. A recent study
from Kenya [3] found that bloodstream infection caused
one quarter of all deaths of children in the hospital, out-
numbering malaria deaths. Antimicrobial resistance
increases worldwide and does not spare developing coun-
tries [6]. However, the impact of antimicrobial resistance
on the clinical outcome of infections such as bloodstream
infection has been difficult to assess due to a number of
factors, including confounding by underlying diseases
[7,8]. We performed a prospective cohort study to gain
knowledge on the etiology and antimicrobial resistance
patterns of pediatric bloodstream infections and to iden-




The study took place from August 2001 to August 2002 at
Muhimbili National Hospital, Dar es Salaam, Tanzania. A
total of 1787 children (aged 0–7 years) were consecutively
enrolled in a prospective cohort study of 1828 admis-
sions. The inclusion criterion was clinical presentation
suspect of systemic infection based on the presence of
fever (> = 38'C), hypothermia (< 36'C) and other signs
and symptoms as detailed in the WHO's IMCI Integrated
Management of Childhood Illness guidelines [9] includ-
ing general danger signs such as convulsions, lethargy,
inability to drink or breastfeed, vomiting, and other signs
of infection, such as neck stiffness, bulging fontanelles,
cough, tachypnea, difficult breathing, chest in-drawings,
nasal flaring, grunting, diarrhea, dehydration, ear or eye
discharge, oral thrush, jaundice, enlargement of liver or
spleen, lymphadenopathy, and signs of infection in the
skin and umbilicus (in neonates). The attending clinician
decided on inclusion of the patient and subsequently
recorded clinical data using a standardized questionnaire
and obtained blood for culture, malaria microscopy and
HIV testing. Additionally, patients' medical records and
departmental registries for admissions, discharges and
deaths were reviewed.
Due to the young age of the study subjects (0 – 7 years),
the parents or other accompanying, responsible family
members were asked for written consent on behalf of the
patient. Information was given in writing and verbally in
the national language, Kiswahili. Written informed con-
sent was obtained before taking blood for microbiological
investigations, if feasible. However, in some circum-
stances, in the case of critically ill patients, blood speci-
mens were taken based on verbal consent, since these
investigations are strongly recommended as routine inves-
tigations in severely ill, febrile children, and since it would
be inappropriate to delay management of such patients
due to paperwork. The responsible family member was
then approached in retrospect for written consent to use
the specimen and information in the study. The responsi-
ble family member was allowed to opt out from the HIV-
testing and only consent to participation in the blood cul-
ture part of the study. As far as possible, the treatment was
guided by the test results. In the following, the term "sus-
pected systemic infection" refers to all included patients in
the study, and the term "laboratory-confirmed blood-
stream infection" refers to growth of one or more clini-
cally relevant bacterial or fungal isolates from blood-
culture from a patient who also confirms to the inclusion
criterion of suspected systemic infection. Viral and para-
sitic infections were not included in the definition of
bloodstream infection.
Community-acquired infection was defined as blood-
stream-infection with growth of pathogenic bacteria in a
blood-culture obtained within the first 48 hours after
admission. For classification purposes, the time to blood-
culture was calculated as the time from admission to the
time of receipt of blood culture in the laboratory, allowing
for overnight delay in transport for cultures obtained in
the evening or at night. A neonate who was born in hos-
pital within the last 10 days was considered as having hos-
pital-acquired infection. If a patient was discharged and
re-admitted within ten days, the episode was considered a
single admission. The Muhimbili University College of
Health Research Ethics Committee approved the study
protocol.
Microbiologic methods
One and five ml blood from neonates and older children,
respectively, were inoculated in BACTEC Myco/F lytic
blood-culturing vials (Becton Dickinson, Franklin Lakes,
NJ), which supports the growth of fungi and bacteria,
including mycobacteria [10]. The blood-cultures were
incubated for six weeks. Positive blood-cultures were sub-
cultured on Columbia II agar base (Oxoid Ltd, Basing-
stoke, UK) with five percent human blood, chocolate agarPage 2 of 14
(page number not for citation purposes)
BMC Infectious Diseases 2007, 7:43 http://www.biomedcentral.com/1471-2334/7/43and MacConckey agar (Difco/BD Diagnostic Systems,
Sparks, MI, USA). The isolates were identified by standard
methods [11], including the use of API20E, API20NE and
API 20 AUX systems (bioMérieux SA, Marcy l'Etoile,
France). Due to economic limitations, we did not perform
anaerobic culture, and, in general, only a single blood cul-
ture was taken from each patient. Thus, the study was not
designed to evaluate the clinical significance of coagulase-
negative staphylococci (CoNS) and bacteria of doubtful
or limited pathogenicity. Consequently, CoNS and prob-
able contaminant such as diphteroids, Bacillus species and
micrococci were not considered pathogens in this study.
Enterococcal isolates were included in the study as patho-
gens. Cultures with polymicrobial growth were consid-
ered clinically relevant if known pathogens were among
the constituent isolates.
Susceptibilities against antimicrobial agents were tested
by the disk diffusion method according to the Clinical
and Laboratory Standards Institute guidelines [12]. Test-
ing for minimum inhibitory concentration (MIC) of anti-
microbials was not routinely performed on all isolates.
However, MIC determination by E-test (AB Biodisk,
Solna, Sweden) was performed for more detailed charac-
terization of the susceptibilities for antimicrobials in
Gram-negative bacteria and enterococci. Gram-negative
bacteria were investigated for extended-spectrum beta-
lactamases (ESBL) with E-test, PCR and DNA sequencing
as described previously [13]. Enterococcal isolates were
investigated by PCR to affirm identity (E. faecalis, E. fae-
cium) and to detect vancomycin resistance (vanA, vanB).
We verified the identity of isolates of S. aureus and
detected resistance to methicillin/oxacillin with a multi-
plex PCR targeting the nuc gene and the mecA gene [14].
Malaria testing was performed by microscopy of Giemsa-
stained thick and thin drop blood smears. HIV testing was
performed anonymously using a rapid test for HIV1/HIV2
antibodies (ACON HIV 1/2, ACON laboratories, Inc. San
Diego, California, USA). HIV antibody-positive sera from
children younger than 18 months were analyzed for HIV-
1 RNA by reverse transcriptase polymerase chain reaction
(RT-PCR) using primers targeting the pol gene, JA17
through JA20 [15], and the vif region OG 462/502 [16].
Data analysis
Data were entered in a database based on the free-of-
charge WHONET software for surveillance of antimicro-
bial resistance available as a download from the World
Health Organization [17,18], and further data manage-
ment was done in Filemaker Database software. Statistical
analysis was performed in Stata 8 (Stata Corporation, Col-
lege Station, Texas, US). Univariate assessment of risk fac-
tors for intra-hospital death was done by Fisher's exact test
with a two-sided P-value and odds ratios and 95% confi-
dence intervals were obtained by the 'logistic' function in
Stata. Significant factors to the level of P < 0.2 from the
univariate analysis and a priori important factors such as
sex, age and underlying diseases were included in the mul-
tivariate analysis. Multivariate analysis was performed by
automated and manual backwards step-wise logistic
regression where factors with P > 0.2 were removed from
the model. We present four logistic regression models
using different subsets of the study population analyzing
cases of laboratory-confirmed bloodstream infection (n =
216) as well as cases of clinically suspected systemic infec-
tion (n = 1527), and for each category we re-analyzed the
data for those who had known HIV status (n = 128 and n
= 790, respectively). Comparisons of medians of time var-




A total of 1787 patients with a median age of 8.5 months
were admitted 1828 times. Forty-four percent (795/1787)
were female. Neonates (median age 3 days, range 0–30)
accounted for almost a third of the admissions (29.3%,
535/1828), and stayed a median of 6 days (range 1–53) in
the hospital. Older children (median age 1 year, range 1
month – 7 years) stayed a median of 7 days (range 1–78)
in the hospital.
The clinical outcome was known for 89.3% (1632/1828)
of the admissions. Among the 17.0% (277/1632) who
died in hospital, 22.4% (n = 62) had laboratory-con-
firmed bloodstream infection, 17.7% (n = 49) had
malaria, 6.5% (n = 18) had concomitant laboratory-con-
firmed bloodstream infection and malaria-parasitemia
and 52.0% (n = 144) had neither. Readmissions com-
prised 3.2% (n = 59) of all admissions (39 and 1 patient
were readmitted once and twice, respectively, 18 patients
had been admitted prior to the study).
Antimicrobial therapy
Information on antimicrobial use was available for 85.2%
(1557/1828) of the admissions. The majority of patients
(93.8%) received antimicrobial therapy (Table 1) and at
least two-thirds (67.2%, 1046/1557) of the patients did
so before blood-culture was taken. There was no formal
empirical regimen for the treatment of sepsis at the hospi-
tal, partly because of the scarcity of local studies on anti-
microbial resistance of relevant bacterial isolates.
However, most neonates received a regimen of ampicillin
+ cloxacillin + gentamicin. One-fifth of the neonates
received ceftriaxone, in most cases as a second-line regi-
men in case of unsatisfactory response to the first regimen.
In older children there was a more diverse pattern of regi-
mens used, in most cases including one or more penicil-
lins (ampicillin, penicillin G or cloxacillin) and eitherPage 3 of 14
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panying localizing signs did impact on the choice of anti-
microbial regimen, most notably in the case of suspected
meningitis in children older than 1 month when a regi-
men based on chloramphenicol and a penicillin would
often be used, and in the case of bloody diarrhea when
erythromycin was often added. Severe malaria was treated
with quinine, while less severe cases were treated with
chloroquine in neonates and pyrimethamine-sulfadoxin
in older children. Oral thrush was treated with nystatin
mixture, but systemic antifungal drugs were rarely used.
Ciprofloxacin was not used in children at the hospital.
Types of bloodstream infections
The incidence of laboratory-confirmed bloodstream infec-
tion was 13.9% (255/1828) of all admissions, 15.9% (85/
535) among neonates and 13.1% (170/1293) among
older children. A single pathogen was recovered from 224
children (12.3%), while 31 (1.7%) had polymicrobial
infection with two (n = 26), three (n = 2) or four isolates
(n = 3). In total, 294 pathogenic bacterial and fungal iso-
lates were recovered (Table 2). Among all laboratory-con-
firmed bloodstream infections, half (128/255) were
defined as potentially hospital-acquired. Salmonella and
Escherichia coli were the most common isolates in commu-
nity-acquired infections, and klebsiella and Staphylococcus
aureus were the most common in hospital-acquired infec-
tions (Table 2). Klebsiella was, by far, the most common
cause of neonatal bloodstream infection, particularly in
early-onset infection (0–6 days of age) where it responsi-
ble for approximately one-third of the cases (Table 3). In
children older than 1 month of age, salmonellae were the
most frequently isolated pathogens (Table 3).
Among all children with suspected systemic infection,
those with laboratory-confirmed bloodstream infection
had three times increased risk of dying (Table 4, Figure 1),
and among those who survived, the duration of hospital
stay was significantly longer than for children without lab-
oratory-verified bloodstream infection (median 8 versus 6
days, P < 0.001). Univariate and multivariate analysis of
risk factors for death are shown in Table 4 and 5, respec-
tively. The mortality rate from Gram-negative blood-
stream infection (45.6%) was more than twice that of
malaria (20.2%) and Gram-positive bloodstream infec-
tion (16.7%). Positive blood-culture with Enterobacte-
riaceae, other Gram-negative bacteria and candida were
independent risk factors for fatal outcome (Table 5, Figure
Table 1: Use of antimicrobial agents in children with suspected systemic infection
Number of children (%) receiving drug
Age of child on blood culture 0–6 days 7–30 days 1 month – 7 years Total
No of patients n = 261 n = 190 n = 1106 n = 1557
Any antibacterial 257 (98.5) 186 (97.9) 1017 (92.0) 1460 (93.8)
- Penicillin - - 301 (27.2) 301 (19.3)
- Ampicillin/amoxicillin 244 (93.5) 165 (86.8) 589 (53.3) 998 (64.1)
- Cloxacillin 244 (93.5) 165 (86.8) 354 (32.0) 763 (49.0)
- Cephalexin - - 27 (2.4) 27 (1.7)
- Cefuroxime - - 37 (3.3) 37 (2.4)
- Ceftriaxone 34 (13.0) 51 (26.8) 118 (10.7) 203 (13.0)
- Chloramphenicol - 2 (1.1) 416 (37.6) 418 (26.8)
- Gentamicin 250 (95.8) 173 (91.1) 504 (45.6) 927 (59.5)
- Amikacin - 1 (0.5) 25 (2.3) 26 (1.7)
- Co-trimoxazole - 3 (1.6) 129 (11.7) 132 (8.5)
- Erythromycin - 2 (1.1) 44 (4.0) 46 (3.0)
- Azithromycin - - 23 (2.1) 23 (1.5)
- Nalidixic acid - - 4 (0.4) 4 (0.3)
- Metronidazole - - 22 (2.0) 22 (1.4)
TB medicines - - 71(6.4) 71(4.6)
Any antimalarial 19(7.3) 23 (12.1) 784 (70.9) 826 (53.1)
- Quinine 6 (2.3) 16 (8.4) 636 (57.5) 658 (42.3)
- Sulfadoxine-pyrimethamine - 1 (0.5) 192 (17.4) 193 (12.4)
- Chloroquine 15 (5.7) 9 (4.7) 7 (0.6) 31 (2.0)
- Amodiaquine - - 12 (1.1) 12 (0.8)
- Artesunate - - 1 (0.1) 1 (0.1)
Mebendazole - - 44(4.0) 44(2.8)
Nystatin (oral) 8(3.1) 13(6.8) 195 (17.6) 216 (13.9)
Systemic antifungal - - 8(0.7) 8(0.5)Page 4 of 14
(page number not for citation purposes)
BMC Infectious Diseases 2007, 7:43 http://www.biomedcentral.com/1471-2334/7/432). In a separate logistic regression model examining only
the pathogen involved, the significant risk factors for
death were, in descending order of odds ratio, growth of
Enterobacter spp. (odds ratio 10.5, P = 0.007), Pseudomonas
aeruginosa (9.7, P < 0.001), Salmonella Typhimurium (6.4,
P = 0.001), E. coli (5.0, P < 0.001), klebsiella (4.5, P <
0.001), and candida (2.5, P = 0.049) (data not shown in
table). Growth of Salmonella Enteritidis, Acinetobacter spp.,
E. faecalis, E. faecium and S. aureus were not significant risk
factors for death.
Malaria
Malaria slides were positive in 21.6% (354/1638).
Malaria parasitemia was neither associated with HIV-
infection (P = 0.227), nor bloodstream infection caused
by any pathogen (P = 0.730), Gram-negative bacteria (P =
Table 2: Frequency (percentage) of bacterial and fungal pathogens* cultured from community-acquired† and hospital-acquired‡ 
bloodstream infection
Organism CA† HA‡ Total
Klebsiella spp. 19 (12.3) 34 (24.5) 53 (18.0)
- Klebsiella pneumoniae 17 31 48
Salmonellae 27 (17.4) 12 (8.6) 39 (13.3)
- Salmonella serovar Typhii 1 1 2
- Salmonella serovar Enteritidis 14 6 20
- Salmonella serovar Typhimurium 11 5 16
- Salmonella serovar Newport 1 0 1
Escherichia coli 24 (15.5) 13 (9.4) 37 (12.6)
Enterobacter spp. 5 (3.2) 4 (2.9) 9 (3.1)
- Enterobacter cloacae 2 4 6
- Other Enterobacter spp. 3 0 3
Other Enterobacteriaceae 4 (2.6) 2 (1.4) 6 (2.0)
- Pantoea spp. 2 0 2
- Serratia marcescens 0 1 1
- Shigella flexnerii 1 0 1
- Citrobacter freundii 1 0 1
- Proteus mirabilis 0 1 1
Total Enterobacteriaceae 79 (51.0) 65 (46.8) 144 (49.0)
Acinetobacter spp. 3 (1.9) 9 (6.5) 12 (4.1)
- Acinetobacter baumannii 0 5 5
- Acinetobacter lwoffii 3 2 5
- Acinetobacter spp. 0 2 2
Pseudomonas aeruginosa 7 (4.5) 6 (4.3) 13 (4.4)
Other Non-Enterobacteriaceae 6 (3.9) 5 (3.6) 11 (3.7)
Pseudomonas spp. 4 1 5
Sphingomonas paucimobilis 2 0 2
Chryseobacterium spp. 0 2 2
Moraxella spp. 0 2 2
Total non-EnterobacteriaceaeGNR 16 (10.3) 20 (14.4) 36 (12.2)
GNR not further specified 5 (3.2) 2 (1.4) 7 (2.4)
Total GNR 100 (64.5) 87 (62.6) 187 (63.6)
Staphylococcus aureus 13 (8.4) 17 (12.2) 30 (10.2)
Enterococci 24 (15.5) 19 (13.7) 43 (14.6)
- Enterococcus faecium 12 9 21
- Enterococcus faecalis 9 6 15
- Enterococcus spp. 3 4 7
Streptococci 3 (1.9) 5 (3.6) 8 (2.7)
- Group B streptococci 1 3 4
- Streptococcus viridans 1 2 3
- Streptococci, not further identified 1 0 1
Total Gram-positive 40 (25.8) 41 (29.5) 81 (27.6)
Mycobacterium tuberculosis 0 (0.0) 1 (0.5) 1 (0.3)
Candida spp. 15 (9.7) 10 (7.2) 25 (8.5)
Total 155 (100.0) 139 (100.0) 294 (100.0)
GNR, Gram-negative rods. *The percentage refers to the proportion of all pathogenic bacterial and fungal isolates. Anaerobes, coagulase-negative 
staphylococci and bacterial isolates of uncertain pathogenicity were not included. † CA: Community-acquired infection, i.e. blood-culture obtained 
≤ 48 hours from of admission. ‡ Hospital-acquired infection: Blood-culture obtained > 48 hours from admission.Page 5 of 14
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klebsiella (P = 1.000), non-typhoid salmonella (P =
0.664). The case-fatality rate was not significantly higher
in patients with malaria parasitemia (20.2%) compared
to those without (16.4%, P = 0.102). However, in patients
with positive malaria slides, mortality was almost three
times higher among those with concomitant Gram-nega-
tive bloodstream infection (45.7% versus 17.2%, P <
0.001).
Susceptibility to antimicrobial agents
Enterobacteriaceae displayed high rates of resistance to
commonly used antimicrobials (Table 6). Only 20% of
community-acquired Enterobacteriaceae isolates was sensi-
tive to ampicillin, while two-thirds were sensitive to gen-
tamicin. Two-thirds of community-acquired salmonellae
were sensitive to chloramphenicol, while half are resistant
to ampicillin and to co-trimoxazole. Isolates of Enterobac-
teriaceae were almost uniformly sensitive to ciprofloxacin.
P. aeruginosa isolates were commonly sensitive to anti-
pseudomonas drugs such as ceftazidime, ciprofloxacin
and tobramicin (Table 7). ESBL phenotype was found in
18% of the Enterobacteriaceae isolates (E. coli 9/37, kleb-
siella 9/53, Enterobacter spp. 5/9, salmonella 1/39 and
Pantoea spp 2/2) involving TEM-63, SHV-2a, SHV-12 and
CTX-M-15 genotypes [13], and in 3 isolates of non-Entero-
bacteriaceae (one Acinetobacter spp. and the 2 Chryseobacte-
rium spp.). ESBL-producing isolates were resistant to
almost all tested antimicrobials except for ciprofloxacin
and meropenem.
The majority of S. aureus isolates were sensitive to com-
monly used anti-staphylococcal agents, including cloxa-
cillin and gentamicin (Table 8). Among the three isolates
phenotypically resistant to oxacillin, only one was availa-
ble for confirmatory detection of the mecA gene by PCR.
The child with confirmed MRSA genotype died, the two
other survived. Ten of 21 E. faecium isolates showed com-
bined resistance to ampicillin and gentamicin (high-
level), but only one patient with bloodstream infection
caused by these organisms died. This combined resistance
trait occurred in both community-acquired (4/12) and
hospital-acquired infections (6/9), and the difference was
not statistically different (P = 0.198). Six of 15 E. faecalis
isolates were high-level gentamicin-resistant (but not
ampicillin-resistant) and were involved in the death of
two patients, among whom one had community-acquired
infection. The majority of candida isolates were suscepti-
ble to fluconazole (96%) and amphotericin B (87%).
Antimicrobial treatment prior to blood culture was signif-
icantly associated with resistance to co-trimoxazole (83%
versus 69%, P = 0.036) and chloramphenicol (59% versus
42%, P = 0.035) in Gram-negative isolates as a group,
with resistance to erythromycin (36% versus 0%, P =
0.014) and chloramphenicol (46% versus 0%, P = 0.005)
Table 3: Episodes of laboratory-confirmed bloodstream infection in different age groups of children
Organism* Early onset† N (%) Late onset‡ N (%) Older§ N (%) Total N (%)
Klebsiella spp. 17 (31.5) 7 (22.6) 12 (7.1) 36 (14.1)
Salmonellae 0 (0.0) 1 (3.2) 32 (18.8) 33 (12.9)
Escherichia coli 6 (11.1) 3 (9.7) 19 (11.2) 28 (11.0)
Enterobacter spp. 4 (7.4) 1 (3.2) 2 (1.2) 7 (2.7)
Other Enterobacteriaceae 1 (1.9) 0 (0.0) 1 (0.6) 2 (0.8)
Total Enterobacteriaceae 28 (51.9) 12 (38.7) 66 (38.8) 106 (41.6)
Acinetobacter spp. 1 (1.9) 0 (0.0) 10 (5.9) 11 (4.3)
Pseudomonas aeruginosa 0 (0.0) 0 (0.0) 9 (5.3) 9 (3.5)
Other non-Enterobacteriaceae 4 (7.4) 0 (0.0) 5 (2.9) 9 (3.5)
Total non-Enterobacteriaceae 5 (9.3) 0 (0.0) 24 (14.1) 29 (11.4)
GNR not further specified 1 (1.9) 1 (3.2) 5 (2.9) 7 (2.7)
Total GNR 34 (63.0) 13 (41.9) 95 (55.9) 142 (55.7)
Staphylococcus aureus 6 (11.1) 5 (16.1) 15 (8.8) 26 (10.2)
Enterococci 3 (5.6) 4 (12.9) 23 (13.5) 30 (11.8)
Group B streptococci 2 (3.7) 1 (3.2) 0 (0.0) 3 (1.2)
Other Streptococcus 1 (1.9) 0 (0.0) 2 (1.2) 3 (1.2)
Total Gram positive 12 (22.2) 10 (32.3) 40 (23.5) 62 (24.3)
Mycobacterium tuberculosis 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.4)
Candida spp. 1 (1.9) 3 (9.7) 15 (8.8) 19 (7.5)
Polymicrobial infections 7 (13.0) 5 (16.1) 19 (11.2) 31 (12.2)
Total 54 (100.0) 31 (100.0) 170 (100.0) 255 (100.0)
GNR, Gram-negative rods. *The percentage refers to the proportion of all episodes of laboratory-confirmed bloodstream infection. Anaerobes, 
coagulase-negative staphylococci and bacterial isolates of uncertain pathogenicity were not included. † Early-onset = age 0–6 days. ‡ Late-onset = 
age 7–30 days. † Older = 1 month – 7 years.Page 6 of 14
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Table 4: Univariate analysis of risk factors for intrahospital death among 1632 children* with suspected systemic infection
Risk factor CFR % (n) OR 95% CI P
Overall 17.0 (277/1632)
Male sex 15.5 (143/920) 0.79 0.61 to 1.03 0.084
Neonate (< 1 m) 14.8 (70/473) 0.80 0.59 to 1.07 0.146
Underlying conditions
Malnutrition 29.3 (71/242) 2.37 1.73 to 3.25 < 0.001
HIV infection (laboratory confirmed) 31.7 (46/145) 2.40 1.60 to 3.59 < 0.001
Other infectious underlying conditions 30.6 (33/108) 2.29 1.48 to 3.52 < 0.001
- Tuberculosis 30.5 (29/95) 2.26 1.43 to 3.58 0.001
- Hepatitis 44.4 (4/9) 3.92 1.04 to 14.67 0.052
- Congenital syphilis 50.0 (1/2) 4.85 0.30 to 77.79 0.313
Other non-infectious underlying conditions 17.1 (20/117) 1.00 0.60 to 1.64 1.000
- Sickle cell disease 3.0 (1/33) 0.15 0.02 to 1.09 0.032
- Neoplasia 60.0 (3/5) 7.32 1.22 to 44.05 0.038
- Congenital heart disease 27.3 (9/33) 1.77 0.82 to 3.83 0.156
Malaria (laboratory confirmed) 20.2 (67/331) 1.29 0.95 to 1.76 0.102
Growth in blood culture of:
Any pathogen 34.9 (80/229) 3.29 2.41 to 4.48 < 0.001
Any GNR 43.5 (64/147) 4.60 3.22 to 6.60 < 0.001
Any Enterobacteriaceae 45.6 (52/114) 4.82 3.25 to 7.15 < 0.001
- E. coli 50.0 (15/30) 5.11 2.47 to 10.59 < 0.001
- Klebsiella spp. 48.9 (22/45) 5.00 2.74 to 9.10 < 0.001
- All non-typhoid Salmonellae 36.4 (12/33) 2.88 1.40 to 5.92 0.007
- Salmonella Enteritidis 21.1 (4/19) 1.31 0.43 to 3.97 0.548
- Salmonella Typhimurium 53.9 (7/13) 5.83 1.94 to 17.48 0.003
- Enterobacter spp. 71.4 (5/7) 12.43 2.40 to 64.43 0.002
Any non-Enterobacteriaceae GNR 40.6 (13/32) 3.46 1.69 to 7.10 0.001
- Pseudomonas aeruginosa 66.7 (8/12) 10.04 3.00 to 33.59 < 0.001
- Acinetobacter spp. 9.1 (1/11) 0.49 0.06 to 3.82 0.702
Gram-positive pathogen† 16.7 (11/66) 0.98 0.50 to 1.89 1.000
- Enterococci 19.4 (7/36) 1.19 0.51 to 2.73 0.655
- E. faecium 6.7 (1/15) 0.35 0.05 to 2.65 0.490
- E. faecalis 28.6 (4/14) 1.97 0.61 to 6.33 0.275
- S. aureus 7.1 (2/28) 0.37 0.09 to 1.58 0.208
Candida 33.3 (8/24) 2.49 1.05 to 5.87 0.049
Polymicrobial infection 41.4 (12/29) 3.56 1.68 to 7.55 0.002
Inappropriate antimicrobial therapy due to:
- ESBL-producing, multiresistant isolates 71.4 (15/21) 12.87 4.95 to 33.48 < 0.001
- Other bacterial resistance (non-ESBL) 37.8 (17/45) 3.14 1.69 to 5.83 0.001
- Any bacterial resistance (ESBL + other) 47.7 (31/65) 5.01 3.02 to 8.31 < 0.001
- Any antimicrobial resistance (including fungi) 43.8 (39/89) 4.39 2.82 to 6.83 < 0.001
Hospital-acquired infection 35.5 (44/124) 3.01 2.03 to 4.46 < 0.001
Readmission stay 15.2 (14/92) 0.87 0.49 to 1.56 0.775
CFR, case-fatality rate; OR, odds ratio; 95%CI: 95% confidence interval; P, p-value calculated with two-sided Fisher's exact test; GNR, Gram-
negative rod; ESBL, extended-spectrum beta-lactamase. *The outcome was known for 1632 among a total of 1828 admissions. † Anaerobes, 
coagulase-negative staphylococci and bacterial isolates of uncertain pathogenicity were not included. ‡ Blood culture obtained > 2 days after 
admission.
BMC Infectious Diseases 2007, 7:43 http://www.biomedcentral.com/1471-2334/7/43in S. aureus and chloramphenicol in E. faecalis (89% ver-
sus 20%, P = 0.023). In addition, all three MRSA isolates
were from patients who had received previous antimicro-
bial treatment, but this was not statistically significant.
Hospital-acquisition of infection was significantly associ-
ated with resistance to amoxicillin-clavulanate and cepha-
losporins in E. coli and with co-trimoxazole-resistance in
klebsiella. The percentage of bloodstream infection epi-
sodes caused by an ESBL-producing organism was not sig-
nificantly different among community-acquired (7%, 9/
127) and hospital-acquired infections 13% (16/128, P =
0.206). Patients with hospital-acquired laboratory-veri-
fied bloodstream infection did not receive inappropriate
antimicrobial treatment more often (41%) than those
with community-acquired infection (42%, P≅0.892).
Impact of causative organism on survival from laboratory-confirmed bloodstream infectionFigu e 2
Impact of causative organism on survival from laboratory-
confirmed bloodstream infection.
Table 5: Logistic regression analysis of risk factors for intra-hospital death from laboratory-confirmed bloodstream infection and 
clinically suspected systemic infection
Characteristic Laboratory-confirmed bloodstream infection Clinically suspected systemic infection
HIV-status analyzed No Yes No Yes
No. of observations n = 216 n = 128 n = 1527 n = 790
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
Male sex * * 0.8 (0.60–1.05) *
Neonate (≤ 1 month) * * * 0.7 (0.45–1.15)
Malnutrition 1.9 (0.95–3.88) * 2.1 (1.47–2.90)‡ 1.6 (0.96–2.55)
HIV infection NA 3.4 (1.22–9.40)† NA 2.1 (1.29–3.26)†
Other underlying infectious disease * * 1.8 (1.13–2.87)† *
Underlying non-infectious disease * * * *
Malaria * * * *
Hospital-acquired infection * * * *
Polymicrobial infection * * * *
Growth in blood-culture of:
- Enterobacteriaceae 3.5 (1.71–7.03)† 5.6 (2.06–14.95)† 3.3 (2.09–5.34)‡ 4.2 (2.27–7.65)‡
- Non -Enterobacteriaceae 2.4 (0.92–6.13) 4.0 (0.99–16.45) 2.4 (1.02–5.46)† 2.7 (0.80–8.81)
- Candida spp. 2.6 (0.91–7.29) 2.9 (0.70–12.09) 2.5 (1.02–6.03)† *
Inappropriate antimicrobial treatment 2.1 (1.09–4.16)† 2.3 (0.95–5.58) 2.1 (1.14–3.93)† 1.7 (0.76–3.73)
OR, odds ratio; 95%CI, 95% confidence interval. *Variables with P > 0.2 were removed from the models. Statistically significant risk factors are 
marked † P < 0.05 and ‡ P < 0.001.
Survival from laboratory-confirmed bloodstream infection and clinically suspected systemic infecti nFigure 1
Survival from laboratory-confirmed bloodstream infection 
and clinically suspected systemic infection.Page 8 of 14
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BMC Infectious Diseases 2007, 7:43 http://www.biomedcentral.com/1471-2334/7/43Inappropriate antimicrobial treatment was a risk factors
for death irrespectively of whether controls were patients
with clinically suspected infection or laboratory-con-
firmed bloodstream infection (Table 5, Figure 3). In those
who survived, inappropriate antimicrobial treatment for
the bloodstream-infection was associated with increased
duration of hospital stay (median 8 days versus 6 days, P
= 0.043).
Hospital-acquired infection was associated with increased
duration of hospitalization (median 10 days versus 6
days, P < 0.001), but was not a significant risk factor for
fatal outcome in the multivariate analysis (Table 5, Figure
4).
HIV-infection
Fifty-one percent (911/1787) of the study subjects were
examined for HIV antibodies and 24.0% (219/911) were
positive. The HIV-1 PCR was positive in 55.4% (82/148)
of children younger than 18 months and 8.9% (5/56) of
neonates. Thus, the HIV-1 prevalence was 1.7% (5/302)
for neonates, 24.4% (147/603) for older children, and the
combined overall prevalence was 16.8% (152/905).
Laboratory-confirmed bloodstream infection was not sig-
nificantly more frequent in HIV-positive children (17.5,
28/160) than in HIV-negative ones (15.5%, 119/766, P =
0.552). However, bloodstream infection was more fre-
quently caused by non-typhoid salmonella in HIV-posi-
tive children (25%, 7/28) than in HIV-negative children
(8.4%, 10/119, P = 0.022). There was no such association
between HIV-infection and bloodstream infection caused
by E. coli (17.9% versus 10.9%, P = 0.339), ESBL-produc-
ing organisms (17.9% versus 10.1%, P = 0.321), candida
(10.7% versus 10.9%, P = 1.000) or other pathogens,
except for bloodstream infection caused by klebsiella,
Table 7: Antimicrobial susceptibility (percentage) of non-Enterobacteriaceae Gram-negative isolates causing bloodstream infection
Antimicrobial P. aeruginosa Acinetobacterspp. Other* Total
CA 7 HA 6 CA 3 HA 9 CA 6 HA 5 CA 16 HA 20
Ampicillin 0 0 0 0 17 0 7 0
Amoxicillin-clavulanate 17 20 67 33 67 0 47 22
Cefuroxime 20 0 67 22 67 25 50 17
Ceftazidime 100 100 67 78 83 50 88 79
Meropenem 100 100 100 100 50 50 85 88
Gentamicin 86 83 33 56 50 50 63 63
Tobramicin 86 100 - - - - - -
Doxycycline 0 0 67 56 100 50 54 47
Co-trimoxazole 0 0 0 0 33 50 14 13
Chloramphenicol 20 0 33 22 67 0 43 13
Ciprofloxacin 100 100 100 78 100 100 100 89
CA, community-acquired infection; HA, hospital-acquired infection; "-", not done. *Other isolates include other Pseudomonas spp., (5), 
Sphingomonas paucimobilis (2), Chryseobacterium spp. (2), Moraxella spp. (2).
Table 6: Antimicrobial susceptibility (percentage) of Enterobacteriaceae isolates causing bloodstream infection
Antimicrobial Klebsiella Salmonella E. coli Other* Total
CA 19 HA 34 CA 27 HA 12 CA 24 HA 13 CA 9 HA 6 CA 79 HA 65
Ampicillin 0 0 52 33 4 15 11 33 20 12
Amoxicillin-clavulanate 53 62 70 67 75 31† 11 17 61 52
Cefuroxime 74 85 93 100 88 54† 56 50 82 78
Ceftazidime 79 85 96 100 88 46† 56 50 85 77
Cefotaxime 78 85 96 100 88 50† 56 67 84 80
Meropenem 100 100 100 100 100 100 100 100 100 100
Gentamicin 53 53 74 67 71 54 33 50 63 55
Doxycycline 58 71 85 75 13 23 33 17 51 57
Co-trimoxazole 37 6† 52 33 13 23 22 50 33 18
Chloramphenicol 47 56 85 67 33 46 22 50 53 55
Ciprofloxacin 100 100 100 100 92 92 89 100 96 98
CA, community-acquired infection; HA, hospital-acquired infection. *Other isolates include Enterobacter spp., (9), Pantoea spp. (2), Serratia 
marcescens (1), Shigella flexneri (1), Citrobacter freundii (1), Proteus mirabilis (1). † Statistically significant difference in susceptibility among hospital-
acquired and community-acquired isolates, p < 0.05 by two-sided Fisher's exact test.Page 9 of 14
(page number not for citation purposes)
BMC Infectious Diseases 2007, 7:43 http://www.biomedcentral.com/1471-2334/7/43which was negatively associated with HIV infection (7.1%
versus 33.6%, P = 0.005). HIV-positive children as a group
did not receive more antimicrobial therapy (97.2% versus
93.4%, P = 0.082). However, the given antimicrobial ther-
apy for those with bloodstream infection was inappropri-
ate more often than in HIV-negative children (64.0%
versus 40.2%, P = 0.044). HIV-infection was a risk factor
for death (Table 5, Figure 5), and associated with signifi-
cantly longer hospital stay in those who survived (median
9 versus 6 days, P < 0.001).
Malnutrition and other underlying conditions
One sixth (15.5%, 248/1603) of the patients were mal-
nourished. Malnutrition was a risk factor for death (Table
5, Figure 6) and, in those who survived, it was associated
with prolonged hospital stay (median 10 versus 6 days, P
< 0.001). Other underlying diseases were grouped into
Survival from community-acquired and nosocomial labora-to y-confir ed bloodstre m inf ctionFigure 4
Survival from community-acquired and nosocomial labora-
tory-confirmed bloodstream infection.
Table 8: Antimicrobial susceptibility (percentage) of Gram-positive bacteria causing bloodstream infection
Drug S. aureus E. faecium* E. faecalis*
CA 13 HA 17 CA 12 HA 9 CA 9 HA 6
Penicillin 0 0 10 0 17 75
Ampicillin* - - 25 11 100 100
Amoxicillin-
clavulanate
77 50 70 11† 100 100
Cloxacillin 92 88 - - - -
Cefuroxime 92 88 - - - -
Ceftazidime 85 80 - - - -
Meropenem 100 100 - - - -
Gentamicin* 100 81 67 33 56 67
Vancomycin* 100 100 100 100 100 100
Erythromycin 100 71 0 0 22 33
Doxycycline 62 35 9 0 25 0
Co-trimoxazole 69 63 27 0 67 40
Chloramphenicol 85 73 50 11 38 33
Ciprofloxacin* 77 81 42 22 100 100
Linezolid* - - 100 100 100 100
Quinupristin-
dalfopristin*
- - 100 100 0 17
CA, community-acquired infection; HA, hospital-acquired infection; "-", not done. *E-test was used for susceptibility testing of enterococci against 
ampicillin, ciprofloxacillin, linezolid, quinupristin-dalfopristin, vancomycin and high-level gentamicin resistance. † Statistically significant difference in 
susceptibility among hospital-acquired and community-acquired isolates, p < 0.05 by two-sided Fisher's exact test.
Impact of antimicrobial resistance on survival from labora-tory- on irmed bloodst am i fectionFigure 3
Impact of antimicrobial resistance on survival from labora-
tory-confirmed bloodstream infection.Page 10 of 14
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titis (n = 9) and congenital syphilis (n = 2) and non-infec-
tious conditions, including sickle cell disease (n = 36),
cancer (n = 5), congenital heart disease (n = 38), asthma
(n = 5), Down's syndrome (n = 11), cerebral palsy (n =
25), congenital malformations (n = 21), epilepsy (n = 10)
and hemophilia (n = 2). Other underlying infectious con-
ditions than HIV were a significant risk factor for fatal out-
come among all patients with clinically suspected
systemic infection.
Discussion
Considering the frequent use of antimicrobials prior to
blood-culture, the study probably underestimates the
incidence of bloodstream infection, particularly episodes
caused by fastidious organisms such as pneumococci and
other organisms susceptible to commonly used antimi-
crobials. Nevertheless, the observed incidence of labora-
tory-confirmed bloodstream infection was high (13.9%)
and comparable to that of malaria (21.6%). The therapeu-
tic dilemma is evident, since bloodstream infection and
malaria are difficult to distinguish based on clinical pres-
entation [4,5]. While mortality was similar in blood-
stream infection and malaria in a study from Rwanda in
the 1980s [19], bloodstream infection carried much
higher mortality than malaria in our study. As reported
recently from Kenya [3], deaths from bloodstream infec-
tion outnumbered malaria deaths. The three times higher
mortality among malaria-parasitemic patients with con-
comitant Gram-negative bloodstream infection under-
lines the relative importance of bloodstream infections.
Prompt antimicrobial treatment is imperative for the sur-
vival of patients with bacterial bloodstream infection
[20]. However, the impact of antimicrobial resistance on
the clinical outcome has not been firmly ascertained, par-
ticularly in developing country settings [6-8,21,22]. The
present study confirms that inappropriate treatment of
bloodstream infections due to antimicrobial resistance
predicts fatal outcome independently of underlying dis-
eases, and is associated with longer duration of hospital
stay in those who survive. While morbidity and cost are
more sensitive measures of the impact of antimicrobial
resistance in rich countries [7], our study demonstrates
that the toll of antimicrobial resistance in Sub-Saharan
Africa is quantifiable in loss of human lives.
The high rates of resistance in Gram-negative bacteria con-
firm previous findings [23]. However, the frequent use of
antimicrobials prior to blood culture may have biased the
findings by lowering the detection rate for organisms sus-
ceptible to commonly used drugs. It is grave that half of
the klebsiella isolates, which are inherently resistant to
ampicillin, are also resistant to gentamicin, since these
two drugs are the most frequently used drugs for the treat-
ment of bloodstream infections. The high incidence and
case-fatality rate of klebsiella bloodstream infection in our
study supports the findings by Zaidi and colleagues that
klebsiella infections may be responsible for more than 0.3
million yearly neonatal deaths globally [22]. As reported
elsewhere [19,24,25], salmonella was the most frequent
cause of bloodstream infections in older children. Non-
typhoid salmonella cause a wide range of manifestations
from self-limiting gastroenteritis to systemic infections
such as bloodstream infections and sometimes meningitis
associated with high mortality [26,27]. Bloodstream
infection caused by Salmonella Typhimurium was associ-
ated with fatal outcome with comparable case-fatality
rates as other major Enterobacteriaceae species, while
bloodstream infection caused by S. Enteritidis was associ-
Impact of nutritional status on survival from laboratory-con-firmed bloodstream infectionFigure 6
Impact of nutritional status on survival from laboratory-con-
firmed bloodstream infection.
Impact of HIV co-infection on survival from laboratory-con-firmed bloodstream infectionFigure 5
Impact of HIV co-infection on survival from laboratory-con-
firmed bloodstream infection.Page 11 of 14
(page number not for citation purposes)
BMC Infectious Diseases 2007, 7:43 http://www.biomedcentral.com/1471-2334/7/43ated with lower case-fatality rates in the same range as
Gram-positive bloodstream infections. The relatively low
case-fatality rate from bloodstream infection caused by S.
aureus reflects the frequent use of cloxacillin and the near
absence of methicillin-resistance. Bloodstream infection
caused by E. faecium resistant to ampicillin and gen-
tamicin is a potentially serious problem considering the
widespread reliance on these drugs for treatment. The rel-
atively low case-fatality rate from bloodstream infection
caused by these organisms may reflect an inherently less
virulent nature. However, it is also possible that some of
the E. faecium isolates may have been skin contaminants,
in which case the study may overestimate the incidence of
bloodstream infection caused by this organism.
Hospital-acquired infection was associated with increased
rate of resistance to cephalosporins in E. coli and co-tri-
moxazole in klebsiella, but it was not a risk factor for fatal
outcome. Possibly, the definition used for hospital-
acquired infection may have been too strict in the current
study setting. The classification as hospital-acquired
depended partly on the difference in time from admission
to time of receiving the blood culture in the laboratory.
Thus, any delay in obtaining or transporting blood-cul-
tures may have led to some cases of community-acquired
infection being wrongly classified as hospital-acquired.
On the other side, it is less likely that cases of community-
acquired infection have been misclassified as such,
although we cannot rule out the possibility of underre-
porting of previous hospitalization.
Candida bloodstream infection was more frequent than
reported from comparable low-income countries [22] and
more in line with the trend in developed countries [28].
Candida bloodstream infection was not associated with
HIV-infection or malnutrition. Candida was as common
as a cause of community-acquired bloodstream infections
(10.2%) as hospital-acquired ones (9.4%, P = 0.837). The
rare use of systemic antifungals may partly explain the
high case-fatality rate associated with candida blood-
stream infection.
The HIV prevalence (16.8%) was higher than the country
average (7%) [29] and the estimate for Dar es Salaam
(10.8%) [30], but lower than in a study of children admit-
ted to the same hospital in 1995–96 (19.2%) [31], in
which HIV status was verified by p24 antigen detection.
The selection of study population (hospitalized children
with fever) and the refusal by some parents to test their
child may have influenced the HIV prevalence estimate.
Co-trimoxazole prophylaxis against Pneumocystis jirovecii
pneumonia has been linked to resistance to this drug in
HIV infected individuals [32-34]. In our study, HIV-posi-
tive subjects did receive inappropriate antibacterial ther-
apy more frequently than HIV-negative, however, there
was no significantly difference in resistance traits when
analyzing for specific organism groups. Malnutrition pre-
disposes patients for bacterial infection and is an underly-
ing factor in more than half of under-five deaths [2]. Our
study support the findings of previous studies that both
malnutrition and HIV infection affect adversely the out-
come of bloodstream infection [2,34,35]. The association
between salmonella infection in HIV-infection is well-
known and has been attributed to a deficiency in the
immune system that permits intracellular survival of the
bacteria despite presumed adequate treatment [24,25,36].
While other infections such as Pneumocystis jirovecii pneu-
monia are important causes of death in HIV-infected chil-
dren [37], our study suggest that bloodstream infection
may contribute to the excess mortality in HIV-infected
children in Sub-Saharan Africa [38].
In contrast to studies on adults from Tanzania and else-
where [39], we isolated Mycobacterium tuberculosis from
blood-culture from only one of 97 children with clinical
tuberculosis. This finding indicates that blood-culture is a
poor diagnostic tool for pediatric tuberculosis and under-
lines the experience from other studies that it is difficult to
establish microbiological evidence to support the diagno-
sis of tuberculosis in children [40].
One limitation of the study is that clinical and outcome
data were missing for some patients. Furthermore, we per-
formed neither anaerobic culture nor repeat cultures to
assess the significance of coagulase-negative staphyloco-
cci. The frequent use of antimicrobials before blood-cul-
ture and the small blood volume cultured, particularly
from neonates (1 ml), likely precluded the detection of
pathogens, particularly fastidious organisms. The blood-
culture system supported growth of pneumococci during
quality testing in our laboratory. While available docu-
mentation by the start of our study supported use of the
blood-culture system [10,41], a later study indicated that
it was not optimal for detection of pneumococci and S.
aureus [42]. Sub-culturing on human blood agar plates
may have interfered with the detection of pneumococci in
the study. Human blood agar, prepared from expired
banked blood, is widely used for bacterial isolation in
developing countries, but has recently been demonstrated
to be inferior to animal blood agars (sheep or horse
blood) in detecting growth of common bacteria such as
pneumococci, S. pyogenes and S. aureus. The use of human
blood agar leads to reduced bacterial colony size, altered
colony morphology and poor hemolysis [43]. The reasons
for this are not fully understood, but may include rem-
nants of antimicrobials consumed by the blood donor,
antibodies or other unknown factors. While citrate in
banked human blood has been considered a possible
explanation for the inferiority of human blood agar forPage 12 of 14
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sheep blood agar to be a practical and superior alternative
to human blood agar [43]. While sheep and horse blood
is often not readily available in many developing coun-
tries, goat or pig blood is more accessible and affordable
and could be used for agar production [44]. A further rea-
son for abandoning the use of human blood agar is the
associated biohazard to the laboratory personnel due to
frequent infection with HIV, hepatitis B and C among
blood donors.
Conclusion
Our study shows that antimicrobial resistance predicts
fatal outcome of bloodstream infection. While malaria
can be treated with highly effective, inexpensive and
widely available quinine, treatment of bacterial and fun-
gal bloodstream infection is compromised by antimicro-
bial resistance and unavailability of expensive second-line
antibacterial and systemic antifungal drugs. The finding
that antimicrobial resistance, HIV-infection and malnutri-
tion independently predicts fatal outcome not only call
for renewed efforts to improve HIV care, nutrition and
general living conditions for children, but also argue for
increased focus on interventions to limit the selection
pressure for resistant organisms such as education on
rational use of antimicrobials, development of judicious
guidelines for treatment strategies and adequate govern-
ment regulation of drug quality and access to antimicro-
bial drugs [45].
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